Kura Oncology
KURA
142 hedge funds and large institutions have $849M invested in Kura Oncology in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 51 increasing their positions, 53 reducing their positions, and 21 closing their positions.
105% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $755K
4% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 53
4% less funds holding
Funds holding: 148 → 142 (-6)
4.25% less ownership
Funds ownership: 107% → 102.75% (-4.2%)
13% less capital invested
Capital invested by funds: $978M → $849M (-$128M)
19% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 21
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$33.6M |
| 2 |
AC
Armistice Capital
New York
|
+$15.6M |
| 3 |
AG
Artal Group
Luxembourg
|
+$8.72M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$8.68M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$8.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$43.5M |
| 2 |
Holocene Advisors
New York
|
-$13.6M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$7.87M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
-$6.83M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$6.11M |
KURA Hedge Fund Activity: Q4 2022 in Review
142 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q4 2022, worth a combined $849M — down 13% from $978M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of KURA and 17 opened new positions — a net loss of 4 holders — while 53 trimmed existing stakes and 51 added.
The largest buyer was Suvretta Capital Management, adding an estimated $33.6M. The largest seller was Deep Track Capital, exiting entirely with an estimated $43.5M sold.
- 142 institutional investors held Kura Oncology (KURA) as of Q4 2022, down from 148 in Q3 2022.
- Funds reported $849M of Kura Oncology stock for Q4 2022, down 13% quarter-over-quarter.
- 17 funds opened new Kura Oncology positions in Q4 2022 and 21 closed out, a net change of -4 holders.
- The largest Kura Oncology buyer in Q4 2022 was Suvretta Capital Management, an estimated $33.6M added.
- The largest Kura Oncology seller in Q4 2022 was Deep Track Capital, an estimated $43.5M sold.
Based on aggregated 13F filings for Q4 2022.